Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are medications that help in relaxing the muscles in the lungs and widening the airways, making it easier to breathe. Suriname, a small country in South America, has seen a steady increase in the demand for bronchodilator drugs over the years.
Customer preferences: Customers in Suriname prefer bronchodilator drugs that are affordable, effective, and easily accessible. They are more inclined towards drugs that have fewer side effects and are available in different forms such as inhalers, nebulizers, and tablets.
Trends in the market: One of the primary reasons for the growth of the bronchodilator drugs market in Suriname is the increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The rise in air pollution levels, smoking, and unhealthy lifestyle habits have contributed to the increase in the number of people suffering from these diseases. As a result, the demand for bronchodilator drugs has increased significantly. Another trend in the market is the growing preference for combination therapies. Combination therapies involve the use of two or more drugs to treat respiratory diseases. They are more effective in improving lung function, reducing symptoms, and preventing exacerbations. The availability of combination therapies in Suriname has increased, and customers are opting for them over single-drug therapies.
Local special circumstances: Suriname has a high prevalence of smoking, which is a significant risk factor for respiratory diseases. According to the World Health Organization, around 30% of the adult population in Suriname smoke. This has led to an increase in the number of people suffering from respiratory diseases, thereby driving the demand for bronchodilator drugs. Moreover, Suriname has a tropical climate, which is conducive to the growth of mold and other allergens. These allergens can trigger respiratory diseases and exacerbate symptoms. As a result, people in Suriname are more susceptible to respiratory diseases, leading to a higher demand for bronchodilator drugs.
Underlying macroeconomic factors: Suriname has a small economy that is heavily dependent on the export of natural resources such as gold, bauxite, and oil. The country has been facing economic challenges in recent years due to declining commodity prices and mismanagement of resources. This has resulted in a decrease in government expenditure on healthcare, leading to a shortage of essential medicines, including bronchodilator drugs. However, the private healthcare sector in Suriname has been growing, and there has been an increase in the number of private clinics and pharmacies. This has led to greater accessibility and availability of bronchodilator drugs in the country. Additionally, the government has been taking steps to improve the healthcare system, which is expected to drive the demand for bronchodilator drugs in the future.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
